Brief: Oncternal Therapeutics Announces Agreement With U.S. FDA On Phase 3 Registrational Study Design For Zilovertamab In The Treatment Of Mantle Cell Lymphoma

Oncternal Therapeutics

04/01/2022 21:17

Jan 4 (Reuters) - Oncternal Therapeutics Inc  ONCT.O :
    * ONCTERNAL THERAPEUTICS ANNOUNCES AGREEMENT WITH U.S. FDA
ON
PHASE 3 REGISTRATIONAL STUDY DESIGN FOR ZILOVERTAMAB IN THE
TREATMENT OF MANTLE CELL LYMPHOMA
    * ONCTERNAL THERAPEUTICS INC - GLOBAL REGISTRATIONAL STUDY
ZILO-301 IS EXPECTED TO BE INITIATED IN Q2 OF 2022
    * ONCTERNAL THERAPEUTICS - FDA PROVIDED POSITIVE FEEDBACK ON
PROPOSED KEY CLINICAL, REGULATORY NEEDS OF CO'S DEVELOPMENT
PROGRAM FOR ZILOVERTAMAB IN MCL
    * ONCTERNAL THERAPEUTICS INC -  CO IS ALSO PLANNING TO
CONDUCT
STUDY ZILO-302 DURING INITIAL FOUR MONTHS OF IBRUTINIB
MONOTHERAPY FROM STUDY ZILO-301
    * ONCTERNAL THERAPEUTICS INC - STUDY ZILO-302 IS AN
OPEN-LABEL
COMPANION STUDY OF ZILOVERTAMAB PLUS IBRUTINIB FOR PATIENTS WHO
HAVE PROGRESSIVE DISEASE

Source text for Eikon:  ID:nGNX7MWBjP 
Further company coverage:  ONCT.O 

 ((Reuters.Briefs@thomsonreuters.com;))